4//SEC Filing
Paggiarino Dario A. 4
Accession 0001562180-24-001293
CIK 0001314102other
Filed
Feb 12, 7:00 PM ET
Accepted
Feb 13, 5:39 PM ET
Size
14.3 KB
Accession
0001562180-24-001293
Insider Transaction Report
Form 4
Paggiarino Dario A.
Chief Medical Officer
Transactions
- Tax Payment
Common Stock
2024-02-09$28.80/sh−2,518$72,518→ 44,787 total - Exercise/Conversion
Common Stock
2024-02-09+4,967→ 41,472 total - Tax Payment
Common Stock
2024-02-09$28.80/sh−2,565$73,872→ 42,222 total - Exercise/Conversion
Restricted Stock Units
2024-02-09−5,833→ 5,834 totalExercise: $0.00Exp: 2032-02-09→ Common Stock (5,833 underlying) - Exercise/Conversion
Restricted Stock Units
2024-02-09−4,967→ 0 totalExercise: $0.00Exp: 2031-02-09→ Common Stock (4,967 underlying) - Exercise/Conversion
Common Stock
2024-02-09+5,833→ 47,305 total
Footnotes (3)
- [F1]No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
- [F2]The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.
- [F3]The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
Documents
Issuer
EyePoint Pharmaceuticals, Inc.
CIK 0001314102
Entity typeother
Related Parties
1- filerCIK 0001574261
Filing Metadata
- Form type
- 4
- Filed
- Feb 12, 7:00 PM ET
- Accepted
- Feb 13, 5:39 PM ET
- Size
- 14.3 KB